Multimodality treatment for recurrent neuroblastoma in the central nervous system

Survival for patients with recurrent central nervous system (CNS) neuroblastoma remains poor. A single‐institutional study demonstrated the potential of multimodality therapy, including compartmental intrathecal radioimmunotherapy (cRIT) with 131I‐3F8 or 131I‐8H9 to increase the survival of neurobla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2023-04, Vol.70 (4), p.e30227-n/a
Hauptverfasser: Desai, Ami V., Elmuti, Lena, Cahaney, Christine, De Guzman, Raymond M., Streby, Keri A., Cohn, Susan L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Survival for patients with recurrent central nervous system (CNS) neuroblastoma remains poor. A single‐institutional study demonstrated the potential of multimodality therapy, including compartmental intrathecal radioimmunotherapy (cRIT) with 131I‐3F8 or 131I‐8H9 to increase the survival of neuroblastoma patients with CNS relapse. However, not all patients are able to receive this therapy. We report three patients with CNS neuroblastoma who remain disease‐free 3–9 years after receiving multimodality treatment without cRIT. Additional studies to identify patients most likely to benefit from cRIT are warranted.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.30227